IN THE CLAIMS:

Claim 1 (amended): A compound, or enantiomers, stereoisomers and tautomers thereof, or pharmaceutically acceptable salts or solvates of said compound, with said compound having the general structure shown in Formula I:



Formula I

M is a moiety having a general structure shown in Formula II[or III]:



II III

where k = 0 or 1, n = 0-5, and p = q = 0, 1 or 2;

V is a moiety selected from the group consisting of C_1-C_8 alkyl; $-(CH_2)_x-A-(CH_2)_y-$; and $-(CH_2)_c-A-(CH_2)_m-C(O)-N(R^7)-(CH_2)_d-$, where A is -O-, $-S(O)_r-$, and $-NR^7-$;

m = 0, 1, 2 or 3; x is a whole number in the range 2-8; y is a whole number in the range 1-5; c is a whole number in the range 2-4; and r= 0, 1 or 2; d is a number in the range 0-5;

X and Y are independently selected from the group consisting of N, and CH;

Z and Z^1 can be the same or different, each being independently selected from the group consisting of N, CH and N(O);

R^1 and R^2 may each number 1-4 and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, polyhalolower alkyl, polyhalolower alkoxy, -OH, CN, NO_2, or $COOR^8$;

B1 cont

R^3 is selected from hydrogen, lower alkyl, lower alkoxy, hydroxyl, with the proviso that when n and k are both 0, then R^3 is not -OH or alkoxy;

A2

R^4 is selected from the group consisting of hydrogen, lower alkyl, polyhalolower alkyl or -OH; and

R^7 and R^8 are independently selected from hydrogen, lower alkyl, substituted or unsubstituted phenyl; and substituted or unsubstituted benzyl, wherein said term "substituted" means optional substitution from one or more moieties selected from the group consisting of alkyl, alkoxy, $-CF_3$, halogen or aryl.

A3 Claim 4 (amended): The compound of claim 1, wherein p and q are independently 0 or 1.

A4 Claim 10 (amended): A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

Please cancel Claim 11 without prejudice.

Please cancel Claim 12 without prejudice.

Please cancel Claim 14 without prejudice.

A5 Claim 16 (amended): A compound exhibiting H_3 antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:



Claim 17 (amended): A compound exhibiting both H_1 and H_3 antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:





Claim 19 (New Claim): The compound of claim 4, wherein Z is N, Z^1 is CH, and p = q = 1.